News
CLLS
2.040
-1.44%
-0.030
Weekly Report: what happened at CLLS last week (0715-0719)?
Weekly Report · 3d ago
Weekly Report: what happened at CLLS last week (0708-0712)?
Weekly Report · 07/15 09:37
Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?
NASDAQ · 07/12 13:59
Weekly Report: what happened at CLLS last week (0701-0705)?
Weekly Report · 07/08 09:38
Monthly information on share capital and company voting rights
Barchart · 07/05 15:30
Weekly Report: what happened at CLLS last week (0624-0628)?
Weekly Report · 07/01 09:38
Cellectis Shareholders Approve Key Resolutions
TipRanks · 06/28 21:30
Cellectis Shareholders Support Management’s Vision
TipRanks · 06/28 20:57
Weekly Report: what happened at CLLS last week (0617-0621)?
Weekly Report · 06/24 09:40
Catalyst Watch: Nike earnings, Datadog event, Norfolk Southern decision, and an oil field-crypto IPO
Seeking Alpha · 06/21 19:00
Cellectis Reveals Advances in Gene Editing Efficiency
TipRanks · 06/20 20:57
Cellectis (CLLS) Upgraded to Buy: Here's Why
NASDAQ · 06/18 16:00
Weekly Report: what happened at CLLS last week (0610-0614)?
Weekly Report · 06/17 09:37
Cellectis Pioneers Non-Viral Gene Therapy for SCD
TipRanks · 06/12 20:58
CELLECTIS UNVEILS A NON-VIRAL GENE THERAPY APPROACH FOR SICKLE CELL DISEASE IN NATURE COMMUNICATIONS
Reuters · 06/12 20:30
Cellectis Is Maintained at Outperform by Oppenheimer
Dow Jones · 06/12 13:37
Cellectis Price Target Cut to $10.00/Share From $11.00 by Oppenheimer
Dow Jones · 06/12 13:37
Oppenheimer Maintains Outperform on Cellectis, Lowers Price Target to $10
Benzinga · 06/12 13:26
Analysts Conflicted on These Healthcare Names: SAGE Therapeutics (SAGE), Bristol-Myers Squibb (BMY) and Cellectis SA (CLLS)
TipRanks · 06/12 12:11
Weekly Report: what happened at CLLS last week (0603-0607)?
Weekly Report · 06/10 09:38
More
Webull provides a variety of real-time CLLS stock news. You can receive the latest news about Cellectis through multiple platforms. This information may help you make smarter investment decisions.
About CLLS
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.